Please assess the completion status of the following clinical trial:

Trial Title: Fibroid Ablation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 28 years of age or older~* Regular, consistent menstrual cycles~* History of excessive bleeding~* One Menstrual Pictogram score ≥ 120 during a one-month screening period~* Baseline Uterine Fibroid Symptom \& Quality of Life (UFS-QOL) Symptom Severity Subscale (SSS) score ≥ 20~* Between 1 and 5 Target Fibroids between 1 cm and 5 cm and/or maximum volume 82.4cc~* At least one fibroid must indent the endometrium~* Subject is not at material risk for pregnancy.~* Subject is willing to maintain use or non-use of hormonal contraception~* Subject is willing to have uniform maintenance (use or non-use) of any antifibrinolytic or nonsteroidal anti-inflammatory agents~Exclusion Criteria:~* Subserosal fibroids with bulk symptoms~* Presence of type 0 intracavitary fibroids~* Any Target Fibroid \> 5 cm in maximum diameter with a volume \> 82.4cc~* Any fibroid that obstructs access of the VizAblate probe~* Postmenopausal by history~* Desire for current or future fertility~* Hemoglobin \< 6 g/dl~* Pregnancy~* Evidence of disorders of hemostasis~* Use of Gonadotropin-releasing hormone (GnRH) agonist or implantable or injectable progestin and/or estrogen, Selective Estrogen Receptor Modulators (SERM) or selective progesterone receptor modulator (SPRM)~* Short-term use of hormonal medication for management of bleeding~* Evidence for current cervical dysplasia~* Endometrial hyperplasia~* Confirmed abdominal / pelvic malignancy within the previous five years~* Active pelvic infection~* Clinically significant adenomyosis~* Previous uterine artery embolization. Previous surgical or ablative treatment for fibroids or menorrhagia within previous 12 months~* Current use of anticoagulant therapy~* Need for emergency surgery to treat fibroid symptoms~* Concomitant intrauterine polyps \> 1.0 cm~* Contraindication to MRI~* Renal insufficiency~* Uncontrolled hypertension lasting 2 years or more~* One or more treatable fibroids that are calcified~* Chronic pelvic pain~* Presence of an extrauterine pelvic mass~* Presence of a tubal implant for sterilization~* Previous pelvic irradiation~* Endometrial cavity length \< 4.5 cm

- Gender: FEMALE
- Minimum Age: 28 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VizAblate treatment (Type: EXPERIMENTAL): VizAblate System: subject acts as her own control

Based on this trial design, predict the completion outcome and termination type (if applicable).